At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Sintilimab with Interleukin-2+CAPOXdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University·interventional·Posted Oct 31, 2023·Updated Jan 21, 2025
In Brief
A Phase 2 clinical trial evaluating Sintilimab with Interleukin-2+CAPOX for Locally Advanced Rectal Adenocarcinoma. Completed, enrolled 33 participants across 1 site.
Detailed Summary
Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for mid-lower locally advanced rectal cancer - a single-center, single-arm, open-label clinical trail.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Rectal Adenocarcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedOct 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedOct 31, 2023
Enrollment StartOct 21, 2023
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.7 years ago
Interventions
Sintilimab with Interleukin-2+CAPOXdrug
Sintilimab with Interleukin-2+CAPOX